mAb and ADC therapy against B7-H3 has been studied in preclinical studies, and Enoblituzumab antibody has been tested in a phase 1 clinical trial in pediatric solid tumor including osteosarcoma (NCT 02982941). Here, CD276 is linked to osteosarcoma.